Cosmo
TOP 100

Rankiano desde hace más de 3 años
12
Publicaciones
Recomendaciones
16
Seguidores
26
Posición en Rankia
15
Posición último año
Resumen
Respuestas 1859
Comentarios 3
Recomendados 4689
Guardados 61
Cosmo 22/01/21 10:30
Ha respondido al tema Chicharros USA - bolsa internacional
Buenas tardes foro! solo recordar que hay un botón en los posts con forma de escudito que se puede poner reportar si algo os parece spam, yo ya lo he hecho! saludos gente de bien!
Ir a respuesta
Cosmo 22/01/21 10:24
Ha respondido al tema Farmas USA
AKUS veo eso,  Dec. 22, 2020, 12:25 PM(RTTNews) - The lockup period of Akouos Inc. (AKUS) expires tomorrow, i.e. on Dec. 23.he iniciado posición 16,7$ , como de costumbre, pequeña y una fracción de lo que estaría dispuesto a meter, ojo, muy ilíquida parece, muy muy seca...
Ir a respuesta
Cosmo 22/01/21 08:33
Ha respondido al tema Farmas USA
Igon, AKUOS (nea, ra)  genética - auditiva, hearing loss ( creo que la única), veo que están preparando también algo genético para pérdida cabellopresentación january 2021ipo hace varios meses a 17, hoy un poc por debajo, maket cap casi 578M, cash x2yearsRecent Business HighlightsAppointed Alan Smith, Ph.D., as chief technology officer – In June 2020, Alan Smith, Ph.D., joined Akouos as chief technology officer. Dr. Smith brings over 30 years of experience in cellular therapeutics and previously served as executive vice president, technical operations at Bellicum Pharmaceuticals.Strengthened board of directors with appointment of Saira Ramasastry – In June 2020, Saira Ramasastry joined the board of directors of Akouos. Ms. Ramasastry currently serves as managing partner of Life Sciences Advisory, a firm that she founded to provide strategic advice and business development solutions for life science companies.Expanded the role of Arthur Tzianabos, Ph.D. to chairman of board of directors – In August 2020, Akouos announced the appointment of its board member Arthur Tzianabos to chairman of the board of directors.Completed upsized Initial Public Offering – In June 2020, Akouos completed its initial public offering of 14,375,000 shares of common stock at a public offering price of $17.00 per share, including the full exercise of the underwriter’s option to purchase additional shares. Gross proceeds from the IPO were $244.4 million and net proceeds from the offering, after deducting underwriting discounts, commissions and offering expenses, were approximately $223.8 million.Presented two posters at the American Society of Gene & Cell Therapy 23rd Annual Meeting – In May 2020, Akouos presented two posters highlighting Akouos’s use of AAVAnc80 vector technology and its potential to address many forms of hearing loss.Second Quarter 2020 Financial ResultsCash Position – Cash and cash equivalents were $333.0 million as of June 30, 2020, as compared to $120.2 million as of March 31, 2020. Total cash, cash equivalents and marketable securities at June 30, 2020 includes total net proceeds of approximately $223.8 million from the company’s IPO in June 2020. Akouos expects the cash balance to fund operations for at least the next two years.Research and Development (R&D) Expenses – R&D expenses were $9.9 million for the second quarter ended June 30, 2020, compared to $4.4 million for the same period in 2019. The increase was primarily due to contract manufacturing costs, the initiation of preclinical IND-enabling studies for AK-OTOF, and the growth in the number of R&D employees and their related activities, as well as the expense allocated to R&D related to Akouos’s leased facilities.General and Administrative (G&A) Expenses – G&A expenses were $2.7 million for the second quarter ended June 30, 2020, compared to $0.7 million for the same period in 2019. The increase was primarily due to the growth in the number of G&A employees and other administrative expenses, as well as the expense allocated to G&A related to Akouos’s leased facilities.Net Loss – Net loss was $12.5 million, or $11.14 loss per share, for the second quarter ended June 30, 2020, compared to $2.0 million, or $3.42 loss per share, for the same period in 2019.creo que voy a iniciar posición, si te interesa y la miras ya comentarás!saludos foro!
Ir a respuesta
Cosmo 21/01/21 13:13
Ha respondido al tema Farmas USA
Gangas¿¿ dónde dónde? a ver qué hay, ya dirás :)
Ir a respuesta
Cosmo 21/01/21 12:10
Ha respondido al tema Chicharros USA - bolsa internacional
Nano deunido 100 tickers!!! todo chicharrada? yo tengo 60 así que tampoco puedo decir mucho jajaaj, eso si, todos elegidos con mimo y muy poco chicharro,, por lo que es bastante estable todo y no tengo que estar pendiente al detalle o si se me va al OTC etc,  puedo decir de cada una la tesis de inversión, como no tradeo y voy a semi largo con todas no se me hace bola en absoluto, ya no sigo al detalle como antes cada sec que salía, etc , a mi esta diversificación me está funcionando
Ir a respuesta